These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26377643)

  • 1. Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection.
    Devrim İ; Devrim F; Bayram N; Aktürk H; Aksay A; Can D; Apa H
    Minerva Pediatr (Torino); 2021 Apr; 73(2):184-187. PubMed ID: 26377643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
    Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Barbeau P; Skidmore B; Alvarez GG
    Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):557-566. PubMed ID: 29573031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for isoniazid hepatotoxicity in children with latent TB and TB: difference from adults.
    Devrim I; Olukman O; Can D; Dizdarer C
    Chest; 2010 Mar; 137(3):737-8. PubMed ID: 20202962
    [No Abstract]   [Full Text] [Related]  

  • 4. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
    Gray EL; Goldberg HF
    Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(8):224-9. PubMed ID: 20203555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital.
    Chung SJ; Lee H; Koo GW; Min JH; Yeo Y; Park DW; Park TS; Moon JY; Kim SH; Kim TH; Sohn JW; Yoon HJ
    Sci Rep; 2020 Apr; 10(1):6462. PubMed ID: 32296096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latent tuberculosis in childhood: tolerability of two different therapeutic approaches.
    Tersigni C; Venturini E; Cordola C; Piccini P; Bianchi L; Montagnani C; Sollai S; Chiappini E; de Martino M; Galli L
    Expert Rev Anti Infect Ther; 2018 Apr; 16(4):359-365. PubMed ID: 29465259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity.
    Hayashi PH; Fontana RJ; Chalasani NP; Stolz AA; Talwalkar JA; Navarro VJ; Lee WM; Davern TJ; Kleiner DE; Gu J; Hoofnagle JH;
    Clin Gastroenterol Hepatol; 2015 Sep; 13(9):1676-82.e1. PubMed ID: 25724701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review.
    Kunst H; Khan KS
    Int J Tuberc Lung Dis; 2010 Nov; 14(11):1374-81. PubMed ID: 20937175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection.
    Bliven EE; Podewils LJ
    Int J Tuberc Lung Dis; 2009 Sep; 13(9):1054-60. PubMed ID: 19723392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of latent tuberculosis infection: An update.
    Lobue P; Menzies D
    Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic.
    Fountain FF; Tolley E; Chrisman CR; Self TH
    Chest; 2005 Jul; 128(1):116-23. PubMed ID: 16002924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs.
    Ronald LA; FitzGerald JM; Bartlett-Esquilant G; Schwartzman K; Benedetti A; Boivin JF; Menzies D
    Eur Respir J; 2020 Mar; 55(3):. PubMed ID: 31980498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection.
    Miyazawa S; Matsuoka S; Hamana S; Nagai S; Nakamura H; Nirei K; Moriyama M
    Intern Med; 2015; 54(6):591-5. PubMed ID: 25786447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.
    Nolan CM; Goldberg SV; Buskin SE
    JAMA; 1999 Mar; 281(11):1014-8. PubMed ID: 10086436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
    Fresard I; Bridevaux PO; Rochat T; Janssens JP
    Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis.
    O'Brien RJ; Long MW; Cross FS; Lyle MA; Snider DE
    Pediatrics; 1983 Oct; 72(4):491-9. PubMed ID: 6604257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis despite latent infection screening and treatment in patients receiving TNF inhibitor therapy.
    Kaptan Y; Suner A; Taş MN; Oksel F; Aksu K; Sayiner A
    Clin Rheumatol; 2021 Sep; 40(9):3783-3788. PubMed ID: 33745083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [FREQUENCY AND RISK FACTORS OF SEVERE LIVER DYSFUNCTION IN ISONIAZID MONO-THERAPY FOR LATENT TUBERCULOSIS INFECTION].
    Ito K
    Kekkaku; 2016 Sep; 91(9):607-616. PubMed ID: 30646464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area.
    Moon HH; Park SY; Kim JM; Park JB; Kwon CHD; Peck KR; Kim SJ; Lee SK; Joh JW
    Ann Transplant; 2017 Jun; 22():338-345. PubMed ID: 28579606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.